Compare CVSA & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CVSA | ACAD |
|---|---|---|
| Founded | 1987 | 1993 |
| Country | United States | United States |
| Employees | 4996 | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 3.8B |
| IPO Year | N/A | 2000 |
| Metric | CVSA | ACAD |
|---|---|---|
| Price | $132.25 | $22.41 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 22 |
| Target Price | ★ $150.00 | $30.55 |
| AVG Volume (30 Days) | 222.2K | ★ 1.5M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 69.12 |
| EPS | N/A | ★ 0.02 |
| Revenue | N/A | ★ $726,437,000.00 |
| Revenue This Year | $9.66 | $18.80 |
| Revenue Next Year | $6.58 | $11.70 |
| P/E Ratio | ★ N/A | $1,127.50 |
| Revenue Growth | N/A | ★ 40.45 |
| 52 Week Low | $96.08 | $19.69 |
| 52 Week High | $119.41 | $28.35 |
| Indicator | CVSA | ACAD |
|---|---|---|
| Relative Strength Index (RSI) | 72.12 | 51.62 |
| Support Level | $111.20 | $21.04 |
| Resistance Level | N/A | $22.91 |
| Average True Range (ATR) | 5.08 | 0.73 |
| MACD | 0.99 | 0.03 |
| Stochastic Oscillator | 95.08 | 55.56 |
Covista Inc is an American healthcare educator, serving more than 97,000 students and supported by a community of alumni across five accredited institutions. Through personalized, tech-enabled education powered by faculty and colleagues, it expands access to healthcare careers and addresses the U.S. healthcare workforce shortage at scale.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.